While the future of Celgene (NASDAQ:CELG) looks bright in terms of the company's promising pipeline, its present is facing some serious threats. In this video, Fool health-care analyst David Williamson tells investors how the company's present success is absolutely tied to its two key drugs, Revlimid and Vidaza. David highlights the threats to these drugs both in the form of generics, as well as very fierce competition.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.